Chemoradiation Followed by Durvalumab in Poor Risk and/or Elderly Patients With Stage III NSCLC
Part of paid clinical trials in Chicago, Illinois.
- Sponsor
- Rush University Medical Center
- Study ID
- NCT04441138
- Phase
- PHASE2
- Status
- Terminated
Conditions
- Stage III Non-small-cell Lung Cancer
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Durvalumab — DRUGAdjuvant Durvalumab in Poor Risk and/or Elderly Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer who have completed concurrent, split course chemoradiation without progression of disease
Study Details
Elderly (age 70 years or older) or \>18 years old AND poor risk (ECOG 2) newly diagnosed stage IIIA-C (AJCC 8th edition) inoperable non-small cell lung cancer (NSCLC) patients are eligible to participate in this phase II open label study of concurrent, split course chemoradiation followed by Durvalumab (MEDI4736).
Key Dates
- Start date
- Feb 25, 2021
- Status verified
- May 2025
- Primary completion
- Mar 31, 2024
- Completion
- Mar 31, 2024
Study Design
- Enrollment
- 10 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Concurrent, Split Course Chemoradiation Followed by DurvalumabConcurrent, Split Course Chemoradiation Followed by Durvalumab (MEDI4736) in Poor Risk and/or Elderly Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer
Primary Outcome Measure
Rate of Split Course Chemoradiation Completion [ Time Frame: 3 months ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Rush University Cancer Center | Chicago | Illinois | 60612 | - |
Find similar trials in Chicago, IL
By research site